Boiron gains more than 2% after announcing first-quarter 2023 sales of €132.3 million, down 9.2%, heavily impacted by the base effect from Covid test sales, without which sales grew by 10.6%.

Sales of non-proprietary homeopathic medicines showed contrasting trends, while sales of homeopathic specialties continued to grow in most countries and across all products.

"Upcoming launches and the current momentum in homeopathic specialties enable us to maintain our sales growth target", says the healthcare group.

Copyright (c) 2023 CercleFinance.com. All rights reserved.